Develops gene therapies, antibodies and non-viral delivery platforms for neurological diseases, and licenses capsids and drug programs to pharmaceutical partners.
10-K for FY2025, filed Mar 9, 2026We are a biotechnology company whose mission is to leverage the power of human genetics to modify the course of and ultimately cure…View ↗
We are advancing our own proprietary pipeline of drug candidates for neurological diseases, with a focus on AD. Our wholly-owned…View ↗
We are collaborating with Neurocrine on three gene therapy programs against undisclosed targets. Two of these three programs have…View ↗
Pharmaceutical partners pay for licenses or options to license drug candidates and for research and development work. Agreements can bring upfront fees, research-cost reimbursements, option and milestone payments, and royalties on licensed-product sales; research-work payments accrue as work is carried out, while royalties are tied to sales.
10-K for FY2025, filed Mar 9, 2026The Company enters into license, option, and collaboration agreements which are within the scope of ASC Topic 606, Revenue from Contracts…View ↗
The Company’s contracts often include development and regulatory milestone payments that are assessed under the most likely amount method…View ↗
For arrangements that include sales-based royalties, including milestone payments based on the level of sales, in which the license is…View ↗
Upfront payments and fees are recorded as contract liabilities within deferred revenue on the consolidated balance sheets until the Company…View ↗
$40.4M
10-K for FY2025, filed Mar 9, 2026
$40.4M ↗
Pharmaceutical companies work with Voyager through licensing and collaboration agreements covering capsids, drug programs and research and development services.
10-K for FY2025, filed Mar 9, 2026We are a biotechnology company whose mission is to leverage the power of human genetics to modify the course of and ultimately cure…View ↗
We are collaborating with Neurocrine on three gene therapy programs against undisclosed targets. Two of these three programs have…View ↗
The Company enters into license, option, and collaboration agreements which are within the scope of ASC Topic 606, Revenue from Contracts…View ↗
No. It lost $119.7M in FY2025.
10-Q for Q3 FY2026, filed Nov 5, 2026
−$24.7MView ↗
8-K, filed Apr 21, 2026
On April 15, 2026, Nathan Jorgensen, Ph.D. notified Voyager Therapeutics, Inc. (the “Company”) of his decision to resign from his position…View ↗
Flat. Revenue was $40.4M in FY2025, about the same as the $37.4M of FY2021.
Proprietary pipeline focus
The earlier prioritized proprietary pipeline paired an ALS gene therapy with an Alzheimer’s antibody; the latest centers the proprietary pipeline on Alzheimer’s tau programs and says investment in APOE gene therapy is paused.
10-K for FY2022, filed Mar 7, 2023 10-K for FY2025, filed Mar 9, 2026In addition to leveraging TRACER capsids in potential licensing arrangements, we are advancing our own proprietary pipeline of drug…View ↗
Competes with Lundbeck, Merck &, Teijin, Eisai, Janssen Pharmaceuticals, UCB, Bristol-Myers Squibb, Prothena, Ionis Pharmaceuticals, Biogen, Dewpoint Therapeutics, WaveBreak Therapeutics, Molefy Pharma, 4D Molecular Therapeutics, Affinia Therapeutics, Apertura Gene Therapy, Capsida Biotherapeutics, Capsigen, Dyno Therapeutics, and Sangamo Therapeutics
10-K for FY2025, filed Mar 9, 2026Our anti-tau antibody program for AD will potentially compete with tau antibodies being developed by Lundbeck LLC, Merck & Co., Inc. in…View ↗
Loading...